Recombinant TSH for radioactive iodine therapy in thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether a medicine called recombinant human thyroid stimulating hormone (rhTSH) can help prepare your body for radioactive iodine (131I) treatment, which aims to destroy any remaining or spreading thyroid cancer cells. It may be a good option if your thyroid cancer has come back or spread and you are able to have radioactive iodine therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have differentiated thyroid cancer (like papillary or follicular) that has come back or spread, and at least one tumor is 10 mm or larger.
- Your blood counts, kidney function, and liver function tests are within safe ranges (your doctor will check these).
- You are not pregnant or planning to become pregnant, and you agree to use effective birth control during and after treatment.
- You do not have poorly controlled heart disease, diabetes, infections, or other serious health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AF-001 for people with thyroid cancer that has spread and can't be removed with surgery. It's for those who didn't benefit from or can't take standard treatments, or who haven't had radioactive iodine therapy yet.
This study tests if a man-made hormone (rhTSH) can make radioactive iodine therapy more effective for people with advanced thyroid cancer that has come back or spread. It aims to see if it helps find and treat cancer that doesn't respond well to standard radioactive iodine.
This Phase 1 study tests how doctors plan a combination of two radiation approaches—external beam radiation and radioactive iodine—for thyroid cancer that is not fully responding to standard treatment. It may help people who still have iodine-avid tumor spots, but whose iodine uptake looks too low to work well with radioactive iodine alone.
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
This study compares two ways of replacing thyroid hormone after radioactive iodine therapy for high-risk thyroid cancer. It aims to find which approach is more effective and better for patients.
This trial is testing whether giving radiation therapy after thyroid surgery can help destroy any leftover cancer cells in people with high-risk differentiated thyroid cancer. It is for those who had surgery but some cancer was still left behind.
Hear when a new Radiotherapy; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.